A new polyvalent Pseudomonas vaccine
- PMID: 402473
- DOI: 10.1099/00222615-10-1-19
A new polyvalent Pseudomonas vaccine
Abstract
This paper describes the preparation, chemical characterisation and immunogenic properties of a new polyvalent pseudomonas vaccine. New cultural methods were devised which allowed a build-up of the immunogen in the cell wall of the bacteria, and mild extraction techniques were used to remove the immunogens from the cell wall of living bacteria without apparent physical or chemical change which might affect immunogenicity. The polyvalent vaccine comprised 16 component vaccines, each a lipid-protein-carbohydrate complex extracted from one of the 16 different serotypes of Pseudomonas aeruginosa. Single injections into mice of each of the 16 component vaccines induced protection against several strains of homologous serotypes within 3 days of vaccination. The polyvalent vaccine induced similar protection against several strains of each of the 16 serotypes. We would like to thank R. E. Dyster, K. Digby and J. Simmonds for their technical assistance.
Similar articles
-
A new polyvalent pseudomonas vaccine.Behring Inst Mitt. 1984 Nov;(76):113-20. Behring Inst Mitt. 1984. PMID: 6441560
-
Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.Br J Exp Pathol. 1975 Feb;56(1):34-43. Br J Exp Pathol. 1975. PMID: 812544 Free PMC article.
-
[Cell-free Pseudomonas vaccine: its immunochemical characteristics and immunogenicity].Zh Mikrobiol Epidemiol Immunobiol. 1987 Nov;(11):44-7. Zh Mikrobiol Epidemiol Immunobiol. 1987. PMID: 3124416 Russian.
-
Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.Arch Roum Pathol Exp Microbiol. 1982 Apr-Jun;41(2):105-14. Arch Roum Pathol Exp Microbiol. 1982. PMID: 6816188 Review. No abstract available.
-
Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Expert Rev Vaccines. 2005 Oct;4(5):645-56. doi: 10.1586/14760584.4.5.645. Expert Rev Vaccines. 2005. PMID: 16221066 Review.
Cited by
-
Pseudomonas aeruginosa immunotherapy.Eur J Clin Microbiol Infect Dis. 1990 Jun;9(6):377-80. doi: 10.1007/BF01979465. Eur J Clin Microbiol Infect Dis. 1990. PMID: 2387289 No abstract available.
-
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.Infect Immun. 1994 Sep;62(9):3608-16. doi: 10.1128/iai.62.9.3608-3616.1994. Infect Immun. 1994. PMID: 7520416 Free PMC article.
-
Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.Int J Med Microbiol. 2007 Sep;297(5):277-95. doi: 10.1016/j.ijmm.2007.03.012. Epub 2007 Apr 27. Int J Med Microbiol. 2007. PMID: 17466590 Free PMC article. Review.
-
Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.Infect Immun. 1986 Feb;51(2):675-86. doi: 10.1128/iai.51.2.675-686.1986. Infect Immun. 1986. PMID: 3080373 Free PMC article.
-
The NBT test in burned patients.Br J Exp Pathol. 1979 Apr;60(2):167-70. Br J Exp Pathol. 1979. PMID: 444418 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources